206 related articles for article (PubMed ID: 34636116)
21. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.
Kong FF; Pan GS; Du CR; Ni MS; Zhai RP; He XY; Shen CY; Lu XG; Hu CS; Ying HM
Radiother Oncol; 2023 Aug; 185():109721. PubMed ID: 37244356
[TBL] [Abstract][Full Text] [Related]
24. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
25. The Dynamic Change in Plasma Epstein-Barr Virus DNA Load over a Long-Term Follow-Up Period Predicts Prognosis in Nasopharyngeal Carcinoma.
Gihbid A; Benzeid R; Faouzi A; El Alami I; Tawfiq N; Benchakroun N; Bendahhou K; Benider A; Guensi A; Khaali W; Chaoui I; El Mzibri M; Cadi R; Khyatti M
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680107
[TBL] [Abstract][Full Text] [Related]
26. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
[TBL] [Abstract][Full Text] [Related]
27. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
28. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
29. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ
Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068
[TBL] [Abstract][Full Text] [Related]
30. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.
Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y
Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237
[TBL] [Abstract][Full Text] [Related]
31. Value of early evaluation of treatment response using
Chen YH; Chang KP; Chu SC; Yen TC; Wang LY; Chang JT; Hsu CL; Ng SH; Liu SH; Chan SC
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):650-660. PubMed ID: 30264225
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis.
Alami IE; Gihbid A; Charoute H; Khaali W; Brahim SM; Tawfiq N; Cadi R; Belghmi K; El Mzibri M; Khyatti M
Pan Afr Med J; 2022; 41():6. PubMed ID: 35145598
[TBL] [Abstract][Full Text] [Related]
33. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases.
Zhang W; Chen Y; Chen L; Guo R; Zhou G; Tang L; Mao Y; Li W; Liu X; Du X; Sun Y; Ma J
Medicine (Baltimore); 2015 May; 94(20):e845. PubMed ID: 25997061
[TBL] [Abstract][Full Text] [Related]
34. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
[TBL] [Abstract][Full Text] [Related]
35. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
[TBL] [Abstract][Full Text] [Related]
36. Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma.
Zhang Y; Li WF; Mao YP; Guo R; Tang LL; Peng H; Sun Y; Liu Q; Chen L; Ma J
Oncotarget; 2016 Feb; 7(8):9576-85. PubMed ID: 26840023
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
38. Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
Shen EY; Hung TM; Tsan DL; Cheng NM; Kang CJ; Huang SF; Hsu CL; Lin CY; Wang HM; Hsieh JC; Cheng AJ; Fan KH; Chang JT
Radiother Oncol; 2022 Dec; 177():1-8. PubMed ID: 35568282
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
